TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20427668

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of prednisolone (synthetic mixed glucocorticoid/mineralocorticoid agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucocorticoid receptor antagonist pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mineralocorticoid receptor antagonism
Number of subjects: 0
Study: 18480556

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 33

Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 33
Study: 16162204

Group type: EXPERIMENTAL
Intervention: Group A: tacrolimus and sirolimus
Number of subjects: 132

Group type: COMPARATOR
Intervention: Group B: mycophenolate mofetil (MMF) and sirolimus
Number of subjects: 132
Study: 12598380

Group type: EXPERIMENTAL
Intervention: Heptavalent pneumococcal conjugate vaccine (7VPnCV)
Number of subjects: 707
Study: 10696418

Group type: EXPERIMENTAL
Intervention: Artesunate plus sulfadoxine-pyrimethamine (4 mg/kg for 3 days and 25 mg/kg sulfadoxine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine alone
Number of subjects: 40
Study: 8738856

Group type: EXPERIMENTAL
Intervention: Intact and dispersed josamycin Solutab tablet (1,000 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Josacine reference sachet (1,000 mg)
Number of subjects: 36
Study: 1750747

Group type: EXPERIMENTAL
Intervention: Smectite
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 56
Study: 7028010

Group type: EXPERIMENTAL
Intervention: Epikeratophakia
Number of subjects: 14

Group type: COMPARATOR
Intervention: Keratomileusis
Number of subjects: 14
Study: 29796601

Group type: EXPERIMENTAL
Intervention: Magnesium oxide (MgO)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control
Number of subjects: 114
Study: 28211186

Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (SNM)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Permacol®
Number of subjects: 58
Study: 26743119

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 23370835

Group type: EXPERIMENTAL
Intervention: High protein intervention combined with education and supportive care (Asha life [AL])
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard protein with usual care (usual care [UC])
Number of subjects: 68
Study: 21610516

Group type: EXPERIMENTAL
Intervention: Interval Training Group (ITG)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Continuous Training Group (CTG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 22
Study: 18295277

Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 19839170

Group type: EXPERIMENTAL
Intervention: Group A: 50 J/cm2/100 J/cm3 (laser/RF), two passes, three treatment sessions 30 days apart
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group B: 30 J/cm2/50 J/cm3, three passes, five treatment sessions 15 days apart
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group A and Group B
Number of subjects: 20
Study: 17590966

Group type: EXPERIMENTAL
Intervention: Music intervention (both live and recorded)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Classical music
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Nonclassical music
Number of subjects: 19

Group type: COMPARATOR
Intervention: Structured music therapy groups
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Passive listening
Number of subjects: 19

Group type: COMPARATOR
Intervention: Preferred music
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Therapist-selected music
Number of subjects: 19
Study: 11062578

Group type: EXPERIMENTAL
Intervention: Static splinting of extensor tendon repairs
Number of subjects: 33
Study: 8617119

Group type: EXPERIMENTAL
Intervention: Cisapride, 10mg per os four times a day for three days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1595912

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 49
Study: 6380179

Group type: EXPERIMENTAL
Intervention: 0.4 g of doxycycline preoperatively
Number of subjects: 102

Group type: COMPARATOR
Intervention: 0.2 g of doxycycline preoperatively and 0.1 g of doxycycline on the first, second and third postoperative day
Number of subjects: 102
Study: 29771270

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Calcineurin inhibitors (Control)
Number of subjects: 30
Study: 28081952

Group type: EXPERIMENTAL
Intervention: Alteplase (1 mg, up to 12 doses, 8 h apart via extraventricular drain)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Saline (0.9% saline, up to 12 doses, 8 h apart via extraventricular drain)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 500

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 500
Study: 26585569

Group type: EXPERIMENTAL
Intervention: Intensive GMA (two sessions per week)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Weekly GMA (one session per week)
Number of subjects: 104
Study: 23180876

Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 141

Group type: COMPARATOR
Intervention: Loss-framed messages
Number of subjects: 141
Study: 21594645

Group type: EXPERIMENTAL
Intervention: Dynamic disparity vergence modification with a test stimulus (4° step) and a conditioning stimulus (4° double step)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Phoria adaptation experiments measuring changes in phoria over a 5‐min period of sustained fixation
Number of subjects: 10
Study: 19905889

Group type: EXPERIMENTAL
Intervention: DJBL
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 18
Study: 17033146

Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM)
Number of subjects: 0
Study: 12639367

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day) plus tibolone (2.5 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day) plus placebo
Number of subjects: 31
Study: 10868555

Group type: EXPERIMENTAL
Intervention: 10 mg loratadine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 10 mg cetirizine
Number of subjects: 60
Study: 9168290

Group type: EXPERIMENTAL
Intervention: Second Step: A Violence Prevention Curriculum
Number of subjects: 790

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 790
Study: 1400054

Group type: EXPERIMENTAL
Intervention: Fluid Replacement (FR) - carbohydrate-electrolyte fluid replacement solution sufficient to replace 80 ± 2% of sweat loss
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Blood Volume Expander (BVX) - 5.3 ml/kg of 6% dextran in saline
Number of subjects: 7

Group type: COMPARATOR
Intervention: No Fluid (NF)
Number of subjects: 7
Study: 2862419

Group type: EXPERIMENTAL
Intervention: 5 mg vitamin K administered at birth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated group (no vitamin K administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin K administered to newborns with normotest levels < 30%
Number of subjects: 0
Study: 29767650

Group type: EXPERIMENTAL
Intervention: Active ultrasound
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham ultrasound
Number of subjects: 20
Study: 26865338

Group type: EXPERIMENTAL
Intervention: Anterior palatoplasty
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (no surgery)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Successful surgery
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Unsuccessful surgery
Number of subjects: 62
Study: 24742314

Group type: EXPERIMENTAL
Intervention: Active psychosocial support intervention (4 interviews with a psychologist and consultation with a job retention physician)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active psychosocial support intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 23215916

Group type: EXPERIMENTAL
Intervention: Oscillatory device (Pulsehaler(TM), Respinova Ltd)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oscillatory device
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (muted sham device)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 20389176

Group type: EXPERIMENTAL
Intervention: 4-liter PEG solution plus magnesium hydroxide
Number of subjects: 173

Group type: COMPARATOR
Intervention: 4-liter PEG solution
Number of subjects: 173
Study: 19277245

Group type: EXPERIMENTAL
Intervention: Omega-3 dietary supplementation (two 1000-mg capsules 3 times a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17163325

Group type: EXPERIMENTAL
Intervention: Primary precut approach (group B)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Conventional approach (group A)
Number of subjects: 291
Study: 14624169

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C, 800 mg vitamin E, 10 mg folic acid
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 10760722

Group type: EXPERIMENTAL
Intervention: IAN + IO injection with 1.8 mL of 1.5% etidocaine hydrochloride containing 1:200,000 epinephrine
Number of subjects: 48

Group type: COMPARATOR
Intervention: IAN + mock IO injection
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: IO injection of etidocaine hydrochloride
Number of subjects: 48
Study: 8740982

Group type: EXPERIMENTAL
Intervention: Evaluation of reporting quality based on 21 principal parameters
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Study score of all investigations
Number of subjects: 102
Study: 1728756

Group type: EXPERIMENTAL
Intervention: Cloxacillin (4 x 1 gr intravenously during 24 h, perioperatively)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Cloxacillin
Number of subjects: 310
Study: 6469079

Group type: EXPERIMENTAL
Intervention: Lactose containing diet (LC diet) - 150 g/d, high protein (112 g/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lactose free diet (LF diet) - normal protein (67 g/d)
Number of subjects: 40
Study: 30758744

Group type: EXPERIMENTAL
Intervention: 250 mg ASA/200 mg paracetamol/50 mg caffeine (test)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 250 mg ASA/200 mg paracetamol (reference)
Number of subjects: 18
Study: 28525958

Group type: EXPERIMENTAL
Intervention: Short thumb orthosis with MCP joint excluded
Number of subjects: 66

Group type: COMPARATOR
Intervention: Short thumb orthosis with MCP joint included
Number of subjects: 66
Study: 25427964

Group type: EXPERIMENTAL
Intervention: Implants with a screwed tapered internal connection placed subcrestally (Group 1)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Implants with a screwed tapered internal connection placed crestally (Group 2)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Implants with an internal conical seal connection placed subcrestally (Group 3)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Implants with an internal conical seal connection placed crestally (Group 4)
Number of subjects: 81
Study: 24595113

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric volume using the two-diameter method
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric volume using the free-tracing method
Number of subjects: 22
Study: 21956192

Group type: EXPERIMENTAL
Intervention: HeartNetCare‐HF (HNC)
Number of subjects: 715

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 715
Study: 19810099

Group type: EXPERIMENTAL
Intervention: Serum IGF-I levels
Number of subjects: 1121
Study: 17660031

Group type: EXPERIMENTAL
Intervention: High-cutoff (HCO) intermittent hemodialysis (IHD) for 4 hours
Number of subjects: 10
Study: 15957832

Group type: EXPERIMENTAL
Intervention: Qinggan Jiangtang tablet (QJT) 3 tabs, twice a day for 1 month
Number of subjects: 60

Group type: COMPARATOR
Intervention: Glucophage 3 tabs, twice a day for 1 month
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (QJT and Glucophage)
Number of subjects: 60
Study: 11867132

Group type: EXPERIMENTAL
Intervention: Proper allocation concealment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomised controlled trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Allocation concealment process
Number of subjects: 0
Study: 10431273

Group type: EXPERIMENTAL
Intervention: iodixanol 320 mgl/ml
Number of subjects: 110

Group type: COMPARATOR
Intervention: ioxaglate 320 mgl/ml
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: iodixanol
Number of subjects: 110

Group type: COMPARATOR
Intervention: ioxaglate
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: iodixanol and ioxaglate
Number of subjects: 110
Study: 7589030

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA, 1.0 g)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ibuprofen (0.8 g)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Paracetamol (1.0 g)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 22
Study: 2209678

Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CYA) 5 mg/kg/day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Azathioprine (AZA) 2 mg/kg/day
Number of subjects: 31
Study: 7470854

Group type: EXPERIMENTAL
Intervention: Natural sentence processing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repeated control presentations of a single word
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Last words in sentences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infrequent change in typeface
Number of subjects: 0
Study: 30700255

Group type: EXPERIMENTAL
Intervention: Reablement program (4-10 weeks)
Number of subjects: 707

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 707
Study: 28181639

Group type: EXPERIMENTAL
Intervention: Withdrawal of fall‐risk‐increasing‐drugs (FRIDs)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 612
Study: 25319761

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol (EE) 30 mcg/desogestrel 150 mcg plus spironolactone 25 mg/day (group A)
Number of subjects: 18

Group type: COMPARATOR
Intervention: ethinyl estradiol (EE) 35 mcg/cyproterone acetate 2 mg (group B)
Number of subjects: 18
Study: 23820059

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg per day
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 21794858

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Magnetic resonance‐guided focused ultrasound
Number of subjects: 0
Study: 19586937

Group type: EXPERIMENTAL
Intervention: Rituximab added to dose-dense and high-dose chemotherapy (R-MegaCEOP14, R-MAD, BEAM) with autologous stem cell transplantation
Number of subjects: 94

Group type: COMPARATOR
Intervention: High-dose chemotherapy without rituximab (MACOP-B, MAD, BEAM)
Number of subjects: 94
Study: 17721968

Group type: EXPERIMENTAL
Intervention: Behaviorally intensive, contingency management treatment
Number of subjects: 118

Group type: COMPARATOR
Intervention: Less-intensive treatment
Number of subjects: 118
Study: 14756849

Group type: EXPERIMENTAL
Intervention: Zolmitriptan (2.5 mg or 5 mg based on migraine severity)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Number of subjects: 579
Study: 11790416

Group type: EXPERIMENTAL
Intervention: Breakfast of 10 or 50 g of carbohydrate (corn flakes)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Snack of 25 g of carbohydrate (corn flakes) after 1 1/2 h
Number of subjects: 150

Group type: COMPARATOR
Intervention: Breakfast consumption
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Midmorning snack after breakfast
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Blood glucose levels
Number of subjects: 150
Study: 9743320

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7978128

Group type: EXPERIMENTAL
Intervention: Three vital capacity breaths of room air during intravenous propofol administration (2.5 mg.kg‐1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No specific instructions (control group)
Number of subjects: 100
Study: 2688586

Group type: EXPERIMENTAL
Intervention: Intravenous nicardipine hydrochloride
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Subsequent treatment with nicardipine after placebo failure
Number of subjects: 123
Study: 1081271

Group type: EXPERIMENTAL
Intervention: Calcium (2 g per day)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Calcium + vitamin D2 (1000 IU calciferol per day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 86
Study: 31287199

Group type: EXPERIMENTAL
Intervention: Combination therapy (mechanical diagnosis therapy and transforaminal epidural steroid injections)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (no intervention while being on the waiting list)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 31648781

Group type: EXPERIMENTAL
Intervention: Experimental antiplatelet treatment strategy
Number of subjects: 15991

Group type: COMPARATOR
Intervention: Reference antiplatelet treatment strategy
Number of subjects: 15991

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 15991
Study: 26290343

Group type: EXPERIMENTAL
Intervention: 28-mm Oxinium head on XLPE (Group C)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: 32-mm Oxinium head on XLPE (Group D)
Number of subjects: 199

Group type: COMPARATOR
Intervention: 28-mm ceramic head on CPE (Group A)
Number of subjects: 199

Group type: COMPARATOR
Intervention: 28-mm ceramic head on XLPE (Group B)
Number of subjects: 199
Study: 22712537

Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg in 0.05 mL) administered intravitreally at three time points: 9 days prior to surgery, 1 month post-surgery, and 2 months post-surgery.
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no ranibizumab).
Number of subjects: 11
Study: 21297499

Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 60
Study: 19263591

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation (600 mg elemental calcium and 5 microg vitamin D, consumed twice a day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 17276974

Group type: EXPERIMENTAL
Intervention: Binasal cannula
Number of subjects: 60

Group type: COMPARATOR
Intervention: Face mask
Number of subjects: 60
Study: 15467494

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 60
Study: 11237808

Group type: EXPERIMENTAL
Intervention: No condom
Number of subjects: 42

Group type: COMPARATOR
Intervention: Condom
Number of subjects: 42
Study: 9560043

Group type: EXPERIMENTAL
Intervention: Normal general movements throughout
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Transient abnormal general movements
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Persistent abnormal general movements
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Echodensities persisting beyond 14 days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Echodensities up to 14 days
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Longitudinal assessment of quality of general movements
Number of subjects: 27
Study: 7700070

Group type: EXPERIMENTAL
Intervention: cilazapril 2.5‐5 mg daily for 6 months
Number of subjects: 23
Study: 3662594

Group type: EXPERIMENTAL
Intervention: Single dose of human growth hormone (hGH)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Pulsatile treatment with human growth hormone (hGH)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Conventional treatment with human growth hormone (hGH)
Number of subjects: 4
Study: 29691197

Group type: EXPERIMENTAL
Intervention: Motivational Intervention‐Medication Therapy Management (MI‐MTM)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard Medication Counseling (SMC)
Number of subjects: 46
Study: 25757403

Group type: EXPERIMENTAL
Intervention: Working Memory Bias Modification (WMBM) task
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control task
Number of subjects: 60
Study: 23793946

Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Electronic calculator
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pen and paper
Number of subjects: 28
Study: 22361397

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 428

Group type: COMPARATOR
Intervention: Bare-metal stents
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Both stent types
Number of subjects: 428
Study: 19731193

Group type: COMPARATOR
Intervention: Fentanyl (n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sufentanil (n=10)
Number of subjects: 20
Study: 18695095

Group type: EXPERIMENTAL
Intervention: Standard automated perimetry for visual field progression
Number of subjects: 258
Study: 15870721

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg) administered in the community setting
Number of subjects: 101

Group type: COMPARATOR
Intervention: Zoledronic acid (4 mg) administered in the hospital setting
Number of subjects: 101
Study: 12832430

Group type: EXPERIMENTAL
Intervention: Head-down tilt
Number of subjects: 10
Study: 11100343

Group type: EXPERIMENTAL
Intervention: Somatostatin 250 mcg i.v. bolus followed by continuous i.v. infusion at a rate of 6 mg/d for 72 h
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ranitidine 300 mg/d by continuous i.v. infusion for 72 h
Number of subjects: 48
Study: 9581001

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Twelve-Step Facilitation Therapy (TSF)
Number of subjects: 1726

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 1726
Study: 8379502

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 6

Group type: COMPARATOR
Intervention: Soybean oil
Number of subjects: 6